Across TCGA pan-cancer cohorts, JPT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated JPT2 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher JPT2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated JPT2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

UCEC, GBM, and HNSC are the cancer types where JPT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	III,IV	1.000	0.274	.002	38	view →
GBM	DFS	Tertile	All	0.294	0.553	.002	20	view →
HNSC	DFS	Tertile	All	0.322	0.947	.014	18	view →
CCRCC	DFS	Quartile	All	0.542	0.878	.009	10	view →
LSCC	DFS	Quartile	All	0.855	0.520	.021	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: JPT2 tumor-vs-normal RNA expression · all JPT2 data types